London, UK & Stanford, CA, USA – September 8, 2023 – In a landmark discovery poised to redefine our understanding and approach to one of the most formidable cancers, an international consortium of scientists has unveiled a critical mechanism driving the aggressive growth of glioblastoma, the most common and lethal adult brain tumour. Their research points to the early and potent influence of extrachromosomal DNA (ecDNA) – rogue, circular fragments of genetic material that exist outside the main chromosomes – as a primary catalyst in the cancer’s rapid development and resistance to treatment. This groundbreaking revelation could usher in a new era for diagnosing, tracking, and treating glioblastoma, offering a much-needed beacon of hope in a field long stymied by therapeutic limitations.
Published today in the prestigious journal Cancer Discovery, the findings represent the first compelling evidence that these cancer-driving ecDNA rings frequently emerge at the very genesis of glioblastoma, in some cases even preceding the full formation of the tumour itself. This precocious appearance, the researchers suggest, lays the groundwork for the cancer’s notorious speed, adaptability, and stubborn refusal to yield to conventional therapies.
The ambitious study was a collaborative tour de force, spearheaded by Dr. Benjamin Werner, a group leader at Queen Mary University of London, and Professor Paul Mischel, the Fortinet Founders Professor at Stanford University. Both are integral members of team eDyNAmiC, a formidable international alliance funded by the Cancer Grand Challenges initiative. Crucial contributions also came from Professor Charlie Swanton at The Francis Crick Institute, further solidifying the interdisciplinary nature of this pivotal research.
A Devastating Diagnosis and a Glimmer of Hope
Glioblastoma multiforme (GBM) stands as a harrowing diagnosis, notorious for its aggressive nature and devastating prognosis. Despite intensive treatments involving surgery, radiation, and chemotherapy, the median survival rate has stubbornly remained around 14 months for decades, with scant improvement in patient outcomes. This grim reality underscores the urgent need for novel strategies that can detect the disease earlier, track its progression with greater precision, and, crucially, disarm its formidable resistance mechanisms.
The scientific community has long grappled with the mysteries surrounding glioblastoma’s relentless progression. While genetic mutations within the main chromosomes have been implicated, they haven’t fully explained the cancer’s rapid evolution and drug resistance. The emergence of extrachromosomal DNA (ecDNA) as a potentially significant player across various adult and paediatric cancers, including glioblastoma, has sparked intense interest. However, the precise role and intricate mechanisms of ecDNA have remained largely enigmatic, presenting one of the "toughest challenges" facing cancer research today, as identified by the Cancer Grand Challenges initiative.
Unmasking the Rogue Rings: What is ecDNA?
To fully appreciate the significance of this discovery, it’s essential to understand what ecDNA is and why it commands such power. Unlike the neatly packaged DNA within our 23 pairs of chromosomes – the stable instruction manuals for our cells – extrachromosomal DNA exists as independent, circular fragments. Imagine the main chromosomes as the bound volumes in a library, containing the core operating instructions for a cell. ecDNA, in contrast, are like loose, unbound scrolls, capable of replicating independently and carrying critical "recipes" – often, potent cancer-driving genes – in multiple copies.
These "rogue rings" are characterized by their remarkable mobility, their ability to amplify specific genes to exceptionally high levels, and their capacity to be unevenly distributed among daughter cells during division. This dynamic nature provides cancer cells with an unparalleled evolutionary advantage. By carrying numerous copies of oncogenes (genes that promote cancer growth) on these unstable circles, tumour cells can rapidly adapt to environmental stresses, including drug treatments, by simply increasing or decreasing the copy number of specific ecDNAs. This inherent plasticity allows glioblastoma cells to quickly develop resistance, making eradication exceedingly difficult. The Cancer Grand Challenges initiative, founded by Cancer Research UK and the National Cancer Institute in the US, recognized the profound implications of ecDNA and in 2022, invested $25 million in team eDyNAmiC – a sprawling, international, cross-disciplinary consortium – to unravel these mysteries and devise strategies to target them. This latest study marks a substantial stride forward in their ambitious mission.
An Archaeological Expedition into Tumor Evolution
To unlock the secrets of ecDNA in glioblastoma, team eDyNAmiC and their collaborators adopted an innovative, "archaeological" approach. Rather than relying on a single, snapshot biopsy, which offers limited insight into a tumour’s complex history, the researchers meticulously "excavated" multiple sites from around glioblastoma tumours. This multi-region sampling strategy, akin to an archaeologist carefully unearthing artifacts from different strata of a historical site, allowed them to construct a detailed spatial and temporal map of the tumour’s evolution.
"We studied the tumours much like an archaeologist would," explains Dr. Benjamin Werner, a senior author of the paper and group leader at the Barts Cancer Institute, Queen Mary University of London. "Rather than taking a single sample, we excavated multiple sites around the tumour, allowing us to build computational models describing how they evolved. We simulated millions of different scenarios to reconstruct how the earliest ecDNAs emerged, spread, and drove tumour aggressiveness, giving us a clearer picture of the tumour’s origins and progression."
The integrated genomic and imaging data collected from patient samples were then fed into advanced computational models. These sophisticated algorithms were designed to simulate countless evolutionary pathways, tracing the lineage and expansion of ecDNAs within the developing tumour. By reconstructing these intricate evolutionary trajectories, the scientists could pinpoint when and where specific ecDNAs first appeared, how they propagated, and what impact they had on the tumour’s behaviour. This pioneering methodology provided an unprecedented view into the deep evolutionary history of glioblastoma, moving beyond simple observation to infer causality.
The Early Drivers: EGFR ecDNA and Aggression
The meticulous analysis yielded a striking revelation: the vast majority of ecDNA rings identified in glioblastoma tumours contained EGFR (Epidermal Growth Factor Receptor), a gene well-known for its role in driving cancer cell proliferation and survival. The presence of EGFR on ecDNA, in multiple copies, effectively supercharges its cancer-promoting capabilities.
Crucially, the study demonstrated that EGFR ecDNA appeared remarkably early in the cancer’s evolutionary timeline – in some patients, even before the tumour had fully formed. This suggests that EGFR ecDNA is not merely a passenger or a late-stage adaptation but an early and powerful instigator of glioblastoma’s development. Furthermore, the researchers observed that these EGFR ecDNAs frequently acquired additional mutations, such as the EGFRvIII variant. This particular variant is an altered form of the EGFR receptor that is constitutively active, meaning it signals for cell growth and division relentlessly, even in the absence of external growth factors. The acquisition of EGFRvIII on ecDNA was consistently linked to even greater tumour aggressiveness and a heightened resistance to existing therapies. This finding sheds light on how glioblastoma rapidly evolves to evade treatment, often rendering initial therapies ineffective over time.
Beyond single-gene amplification, the study also confirmed a critical characteristic of ecDNA: its capacity to carry more than one cancer-driving gene simultaneously. This "multi-gene cargo" capability means that ecDNA can provide a tumour cell with a formidable arsenal of oncogenes, each potentially contributing to the tumour’s unique evolutionary trajectory and its response (or lack thereof) to treatment. This complex interplay of multiple oncogenes on ecDNA underscores the challenge of targeting glioblastoma effectively with a single drug and highlights the potential value of highly individualized, ecDNA-informed therapeutic strategies.
A Window of Opportunity: Towards Earlier Detection and Smarter Treatments
The early appearance of EGFR ecDNA, particularly before the emergence of more aggressive variants like EGFRvIII, presents a tantalizing "window of opportunity." This critical interval, identified by the researchers, could be exploited for earlier detection and more effective intervention.
"These subtle mechanisms show that there may be a window of opportunity to detect and treat the disease between the first appearance of EGFR ecDNA and the emergence of these more aggressive variants," suggests Dr. Magnus Haughey, a postdoctoral researcher in Dr. Werner’s group and one of the paper’s lead authors. "If scientists can develop a reliable test to detect early EGFR ecDNA – for example through a blood test – it could enable them to intervene before the disease becomes harder to treat."
The prospect of a non-invasive blood test, or "liquid biopsy," capable of detecting these early ecDNA markers holds immense promise. Such a test could revolutionize glioblastoma diagnosis, allowing clinicians to identify the cancer at its nascent stages, potentially even in asymptomatic individuals at high risk, or to monitor recurrence with unprecedented sensitivity. Early detection would enable intervention before the tumour becomes large, infiltrative, and laden with resistance-conferring mutations, dramatically improving the chances of successful treatment.
Furthermore, the discovery that ecDNA profiles can uniquely shape how tumours evolve and respond to therapy reinforces the growing paradigm of personalized medicine. By understanding the specific ecDNA landscape of an individual patient’s tumour, clinicians could tailor treatments more precisely, selecting therapies that target the amplified genes on ecDNA or devising strategies to destabilize the ecDNA itself. This move away from a one-size-fits-all approach towards highly individualized, ecDNA-informed therapies could be a game-changer for glioblastoma patients.
Expert Voices on a Transformative Discovery
The significance of these findings resonated deeply within the scientific and medical communities, drawing enthusiastic responses from the study’s leaders and the broader cancer research establishment.
Professor Charlie Swanton, Deputy Clinical Director and head of the Cancer Evolution and Genome Instability Laboratory at The Francis Crick Institute, and Chief Clinician at Cancer Research UK, emphasized the transformative potential: "These findings suggest that ecDNA is not just a passenger in glioblastoma, but an early and powerful driver of the disease. By tracing when and how ecDNA arises, we open up the possibility of detecting glioblastoma much earlier and intervening before it becomes so aggressive and resistant to therapy. I hope this might help to drive a new era in how we diagnose, track and treat this devastating cancer." His statement underscores the shift in understanding from ecDNA as a mere consequence to a primary cause, opening new avenues for therapeutic intervention.
Professor Paul Mischel, MD, the Fortinet Founders Professor and professor and vice chair of research in the pathology department at Stanford Medicine, highlighted the broader implications of ecDNA research: "These findings reveal an important new insight into the role of ecDNA in tumour development and progression. Previous work from our collaborative team and other researchers, has shown that ecDNA can arise early in tumor development, including at the stage of high-grade dysplasia, and it can also arise later to drive tumor progression and treatment resistance. The findings here show that in glioblastoma, there is an early event driven by ecDNA that could potentially be more actionable, raising the possibility that glioblastoma is another cancer for which earlier detection and intervention based upon ecDNA may be possible." His comments place this study within the larger context of ecDNA’s multifaceted roles in cancer, reinforcing the idea that this mechanism holds generalizable importance across different cancer types.
Dr. David Scott, Director of Cancer Grand Challenges, lauded the study as a testament to the initiative’s mission: "This study exemplifies the bold, boundary-pushing science Cancer Grand Challenges was created to support. By unravelling the evolutionary history of ecDNA in glioblastoma, team eDyNAmiC is not only deepening our understanding of one of the most devastating cancers but also illuminating new paths for earlier detection and treatment. It’s a powerful reminder that when we bring together diverse disciplines and global talent, we can begin to solve the toughest problems facing cancer research." Dr. Scott’s statement highlights the value of large-scale, collaborative funding in tackling complex biological questions that individual labs might struggle to address.
Pioneering the Future: Next Steps for Team eDyNAmiC and Cancer Grand Challenges
While this study represents a monumental leap forward, the researchers acknowledge that many mysteries surrounding ecDNA still remain. The next phase of their work will focus on understanding how different therapeutic regimens impact the number and types of ecDNA within glioblastoma tumours. This research is critical for developing strategies that not only target the genes on ecDNA but also aim to eliminate or destabilize the ecDNA structures themselves, thereby preventing the tumour from evolving resistance.
Team eDyNAmiC is committed to extending its investigations beyond glioblastoma, exploring the role of ecDNAs across a broader spectrum of cancer types. This expanded research will be crucial for uncovering whether the mechanisms observed in glioblastoma are universal to other aggressive cancers or if ecDNA exerts its influence in unique ways depending on the cancer type. Such insights could unlock further opportunities for earlier diagnosis, more precise tracking of disease progression, and the design of smarter, more effective treatments across the oncology landscape.
The ongoing work of team eDyNAmiC, fueled by the visionary support of Cancer Grand Challenges, embodies the spirit of relentless scientific inquiry. By systematically dissecting the complex world of extrachromosomal DNA, these scientists are not merely advancing academic knowledge; they are actively forging new pathways towards a future where glioblastoma, and potentially many other devastating cancers, can be detected earlier, treated more effectively, and ultimately, overcome. This discovery marks a profound turning point, offering a renewed sense of urgency and optimism in the enduring fight against cancer.
About the Author
